Jazz Pharmaceuticals (JAZZ) is drawing fresh attention after announcing six scientific presentations at the 2026 American Academy of Neurology meeting, which will feature new clinical data on Epidiolex across epilepsies and Xywav in narcolepsy.

The shares have been firming up, with a 16.46% 90 day share price return and a 96.29% 1 year total shareholder return. This suggests recent enthusiasm is building around the pipeline news and broader neuroscience portfolio.

If this kind of specialist healthcare story interests you, it may be a good time to look at other names in the space using the 35 healthcare AI stocks

With Jazz trading at US$199.33, at roughly a 12% discount to the average analyst price target and highlighted as having a strong intrinsic discount, investors may ask whether there is still value available or if the market has already priced in future growth.

Most Popular Narrative: 9.1% Undervalued

At $199.33 against a most-followed fair value of $219.40, the narrative frames Jazz as modestly undervalued, with that gap tied closely to HER2 oncology potential.

The description of Ziihera as a "pipeline in a drug," with potential across HER2+ cancers where Herceptin and Enhertu are current standards of care, underpins views that the addressable market is broad and that additional indications could provide multiple shots on goal for revenue expansion.

Want to see what sits behind that fair value uplift? The narrative leans heavily on future revenue mix, margin recovery and a specific earnings profile that is described as anything but conservative.

Result: Fair Value of $219.40 (UNDERVALUED)

However, investors still need to factor in patent expiry risk around the sleep franchise and high debt from past deals, which could pressure margins and reduce financial flexibility.

Next Steps

With both clear risks and potential rewards in play, you may want to move quickly, review the numbers yourself, and decide where you stand. Start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Jazz has caught your attention, do not stop there. Broaden your watchlist now so you are not looking back wishing you had acted sooner.

• Target potential mispricings before others notice by scanning 60 high quality undervalued stocks that combine quality fundamentals with room for upside.
• Prioritise resilience with 72 resilient stocks with low risk scores so your portfolio is anchored by companies that score well on financial strength and risk checks.
• Hunt for tomorrow's standouts using the screener containing 23 high quality undiscovered gems that highlight quality businesses still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.